Correspondence 0000950170-24-005130 from Evoke Pharma Inc (EVOK) (CIK 0001403708)
Evoke Pharma Inc (EVOK) (CIK 0001403708)
Date: Jan. 17, 2024 · CIK: 0001403708 · Accession: 0000950170-24-005130
AI Filing Summary & Sentiment
File numbers found in text: 333-275443
Letter
Re: Evoke Pharma, Inc.
January 17, 2024
VIA EDGAR
Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549
Registration Statement on Form S-1, as amended
File No. 333-275443
Ladies and Gentlemen:
Reference is made to the letter from the undersigned representatives of the underwriters of the proposed public offering of securities of Evoke Pharma, Inc. (“the “Company”), filed as correspondence via EDGAR on January 16, 2024, in which the undersigned joined the Company and requested that the effective date of the Registration Statement on Form S-1 referred to above (the “Registration Statement”) be accelerated so that it would become effective at 5:00 P.M. Eastern Time on January 17, 2024, or as soon as practicable thereafter (the “Effective Time”), pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended.
We hereby join with the Company’s request that such Registration Statement no longer be declared effective at the Effective Time, and we hereby withdraw our request for the acceleration of the effective date until providing further notice.
If you have any questions regarding the foregoing, please do not hesitate to contact Stephen Cohen of Sheppard, Mullin, Richter & Hampton LLP, counsel to the underwriters, at (212) 653-8166.
[Remainder of Page Intentionally Left Blank]
-1-
Very truly yours,
Craig-Hallum Capital Group LLC
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
January 17, 2024
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re: Evoke Pharma, Inc.
Registration Statement on Form S-1, as amended
File No. 333-275443
Ladies and Gentlemen:
Reference is made to the letter from the undersigned representatives of the underwriters of the proposed public offering of securities of Evoke Pharma, Inc. (“the “Company”), filed as correspondence via EDGAR on January 16, 2024, in which the undersigned joined the Company and requested that the effective date of the Registration Statement on Form S-1 referred to above (the “Registration Statement”) be accelerated so that it would become effective at 5:00 P.M. Eastern Time on January 17, 2024, or as soon as practicable thereafter (the “Effective Time”), pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended.
We hereby join with the Company’s request that such Registration Statement no longer be declared effective at the Effective Time, and we hereby withdraw our request for the acceleration of the effective date until providing further notice.
If you have any questions regarding the foregoing, please do not hesitate to contact Stephen Cohen of Sheppard, Mullin, Richter & Hampton LLP, counsel to the underwriters, at (212) 653-8166.
[Remainder of Page Intentionally Left Blank]
-1-
Very truly yours,
Craig-Hallum Capital Group LLC
By: /s/ Rick Hartfiel
Name: Rick Hartfiel
Title: Head of Investment Banking
Laidlaw & Company (UK) Ltd.
By: /s/ Hugh Regan
Name: Hugh Regan
Title: Executive Director
cc: David A. Gonyer, Evoke Pharma, Inc.
Richard A. Friedman, Sheppard, Mullin, Richter & Hampton LLP
Matthew T. Bush, Latham and Watkins LLP